KemPharm Inc

NASDAQ:KMPH   10:45:36 AM EDT
6.12
-0.05 (-0.81%)
Products, Regulatory

Kempharm Inc Now Expects To Finalize SDX Development Plan And Commercial Value Assessment In Early 2022

Published: 12/14/2021 13:05 GMT
KemPharm Inc (KMPH) - Kempharm, Inc. Announces Top-line Results From Clinical Trial Evaluating Safety and Pharmacokinetics of "higher-dose Sdx".
Kempharm - Now Expect to Finalize Sdx Development Plan and Commercial Value Assessment in Early 2022.
Kempharm Inc - Expects to Provide an Update on Plans to Expand Its Pipeline in Early Q1 2022.
Kempharm - Data Reveal Sdx is Well-tolerated, Yields Dose-proportional D-mph Exposure, and Produces Targeted Biological Effects.